Press releases

HeartLogic is the first and only heart failure diagnostic in an implantable device shown to provide weeks of advance notice of an impending heart failure event.

Data presented demonstrate alert improves heart failure risk prediction

Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...

"Our strong financial performance in the first half of 2017 reflects our innovative portfolio,” said CEO Mike Mahoney.

Investor meeting will cover Boston Scientific’s business and long-term growth strategies, including by expanding category leadership and driving global growth.

Industry's first MR-conditional directional DBS System with stimulation visualization

Results from evaluation of real-world patients presented at American Thoracic Society International Conference

The first head-to-head pivotal study comparing two different TAVI platforms demonstrated the LOTUS™ Valve System’s superior efficacy.

BAcquisition expands company's structural heart portfolio; increases offerings for the treatment of patients with valvular heart disease

Largest prospective study of the WATCHMAN device presented as late-breaking trial at Heart Rhythm 2017